Array BioPharma (ARRY) Given Daily Media Sentiment Score of 0.12

News articles about Array BioPharma (NASDAQ:ARRY) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Array BioPharma earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.4058972961826 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

Array BioPharma (NASDAQ ARRY) remained flat at $$10.78 during trading hours on Tuesday. The company’s stock had a trading volume of 4,313,061 shares, compared to its average volume of 3,857,092. The company has a debt-to-equity ratio of 0.54, a quick ratio of 5.43 and a current ratio of 5.43. Array BioPharma has a 52-week low of $6.73 and a 52-week high of $13.40.

Array BioPharma (NASDAQ:ARRY) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). The business had revenue of $29.75 million for the quarter, compared to analysts’ expectations of $33.74 million. Array BioPharma had a negative return on equity of 158.70% and a negative net margin of 89.30%. The company’s revenue for the quarter was down 24.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.20) earnings per share. sell-side analysts predict that Array BioPharma will post -0.99 EPS for the current fiscal year.

A number of research firms have commented on ARRY. BidaskClub cut Array BioPharma from a “hold” rating to a “sell” rating in a research note on Saturday. SunTrust Banks restated a “buy” rating and set a $16.00 price target on shares of Array BioPharma in a research note on Wednesday, November 1st. Stifel Nicolaus restated a “buy” rating on shares of Array BioPharma in a research note on Wednesday, November 1st. Cantor Fitzgerald set a $15.00 price target on Array BioPharma and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $18.00 price target (up from $14.00) on shares of Array BioPharma in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $13.65.

In other news, Director Kyle Lefkoff sold 38,865 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $12.31, for a total value of $478,428.15. Following the sale, the director now directly owns 51,585 shares in the company, valued at $635,011.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.18% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Array BioPharma (ARRY) Given Daily Media Sentiment Score of 0.12” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/05/array-biopharma-arry-given-daily-media-sentiment-score-of-0-12.html.

About Array BioPharma

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Insider Buying and Selling by Quarter for Array BioPharma (NASDAQ:ARRY)

What are top analysts saying about Array BioPharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Array BioPharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit